Recommended
Recommended
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Madrigal Pharmaceuticals Inc (NQ: MDGL )

319.58 +60.24 (+23.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 Next >
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals. 
Via Investor's Business Daily
1 Incredible Growth Stock That Could Turn $200,000 Into $1 Million by 2030
This clinical-stage biopharma stock could harbor one of the best-selling drugs of all time. 
Via The Motley Fool
3 Incredible Growth Stocks to Buy if the Market Dips
These top growth stocks sport premium valuations for a very good reason. 
Via The Motley Fool
2 Surging Healthcare Stocks That Are Still Worth Buying
These two NASH drugmakers have a lot of room to run. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for January
These healthcare stocks have a lot going for them in the new year. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years
Via Benzinga
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,800 Today
Via Benzinga
Analyst Ratings for Madrigal Pharmaceuticals
Via Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
5 Top Stocks for January
Now is the time to begin crafting your watch list for 2023. 
Via The Motley Fool
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common... 
Via Benzinga
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results. 
Via The Motley Fool
Stock Market Falls Sharply Again As Tesla Dives, Micron Hits Chips; Nike, FedEx Strong: Weekly Review
The market uptrend is under pressure. 
Via Investor's Business Daily
Universal Health Services, Madrigal Pharmaceuticals And These Overbought Majors In The Healthcare Sector
The most overbought stocks in the healthcare sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Madrigal Pharmaceuticals Was a Top Stock This Week
Biotech bulls stampeded the company following its latest clinical update. 
Via The Motley Fool
7 Drug Stocks That Will Soar in 2023
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years. 
Via InvestorPlace
Earnings Optimism Puts Wind In Wall Street's Sails
The major indexes are extending their rally off a mid-December losing streak. 
Via Talk Markets
Why Did Viking Therapeutics Stock Skyrocket
VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial. 
Via MarketBeat
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
Via Benzinga
Madrigal Pharmaceuticals Gets Price Target Bumps By Analysts Following Successful NASH Study
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) announced positive topline results from the pivotal Phase 3 MAESTRO-NASH biopsy trial of resmetirom. Madrigal Pharmaceuticals shares jumped 268.1% to close... 
Via Benzinga
Peering Into Madrigal Pharmaceuticals's Recent Short Interest
Madrigal Pharmaceuticals's (NASDAQ:MDGL) short percent of float has risen 3.82% since its last report. The company recently reported that it has 2.16 million shares sold short, which is 15.49% of all... 
Via Benzinga
Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close... 
Via Benzinga
Here's How An Options Trader Made $5.5 Million In One Day
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) shares rose sharply on Monday after the company announced positive topline results from the pivotal Phase 3 MAESTRO-NASH (fatty liver disease) 
Via Benzinga
Tesla, Amazon, Apple, Madrigal, Walt Disney: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed in the red on Monday as investor optimism on the much-anticipated Santa Claus rally began to fade over fears of recession gaining momentum. 
Via Benzinga
Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro
The biotech sector has not done well in 2022 despite some strong runs. Small and mid-cap stocks are more “risk-off’ with interest rates rising and sentiment waning. 
Via Talk Markets
Madrigal Pharmaceuticals (NASDAQ: MDGL) Reports Impressive Topline Results from Phase 3 Trial of Resmetirom to Treat NASH and Liver Fibrosis
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Dow Struggles To Maintain Morning Gains
This morning's rally was short-lived, and by midday, the major indexes were trading back in the red amid looming recession anxieties. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.